Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial

What Was Tested

Researchers studied Semaglutide in this randomized controlled trial publication.

Who Took Part

The abstract describes 120 people taking part.

By PubMed's age tags, the people studied were middle-aged adults.

Secondary outcomes included changes in kidney perfusion, erythropoietin, haematocrit, urine albumin/creatinine ratio (UACR) and GFR (measured using technetium-99m) compared with baseline and between treatment groups at week 32.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label, placebo-controlled and parallel-group study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the people and researchers unaware of who received Semaglutide.

Nothing was hidden in this open-label Semaglutide study: the people and staff both knew the treatment.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

The trial was undertaken at Aarhus University Hospital, Denmark.

The two co-primary outcomes were change in kidney oxygenation and change in arterial stiffness.

This paper reports on kidney oxygenation, for which 80 individuals as prespecified, 20 in each group, underwent MRI.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Hypoglycemic Agents, Kidney, Perfusion, Erythropoietin, Semaglutide and Benzhydryl Compounds.

The authors tagged it with the keywords Glucagon-like peptide-1 receptor agonist, MRI, Sodium–glucose cotransporter 2 inhibitor and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Semaglutide in 120 people.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Diabetologia), a journal based in Germany.

More context: the Semaglutide compound page, all human trials.